{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:59:44Z","timestamp":1785221984049,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that often persists into adulthood, negatively impacting occupational, social, and economic outcomes. The Adult ADHD Investigator Symptom Rating Scale (AISRS) is a clinician-administered tool designed to evaluate ADHD symptom severity and treatment response. However, a validated Japanese version is not available. This study evaluated the reliability and convergent validity of the Japanese version of the AISRS (AISRS-Japanese) in adults with ADHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following linguistic validation procedures, the AISRS was translated into Japanese and reviewed by clinicians for conceptual and clinical equivalence. This was a multicenter, longitudinal, non-interventional study assessing the psychometric properties of the AISRS-Japanese. The evaluation instruments were the AISRS-Japanese, the Adult ADHD Self-Report Scale (ASRS-Japanese version), and the Clinical Global Impressions-Severity (CGI-S) scale. Reliability assessments included internal consistency (Cronbach\u2019s alpha), test-retest, intra-rater, and inter-rater reliability (intraclass correlation coefficient [ICC] and G(q,k) coefficients). Convergent validity was evaluated via Pearson\u2019s correlation between AISRS-Japanese and ASRS-Japanese version scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 61 adults with ADHD were included in the analysis. The mean age of the study participants was 34 years, 52.5% (32\/61) were male, and 75.4% (46\/61) were moderately ill (CGI-S score of 4). The AISRS-Japanese demonstrated internal consistency for the total scale (Cronbach\u2019s alpha = 0.83) and the hyperactivity\/impulsivity and inattention subscales (0.76 and 0.75, respectively). Test-retest reliability was good (ICC: total, 0.77; hyperactivity\/impulsivity, 0.79; inattention, 0.83), as was intra-rater reliability (ICC: total, 0.76; hyperactivity\/impulsivity, 0.77; inattention, 0.83). Inter-rater reliability was excellent (G(q,k): total, 0.96; hyperactivity\/impulsivity, 0.97; inattention, 0.96). Convergent validity of the ASRS-Japanese version was high (correlation coefficient: total, 0.89; hyperactivity\/impulsivity, 0.88; inattention, 0.84).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results provide evidence supporting the reliability and convergent validity of AISRS-Japanese as a semi-structured tool for assessing ADHD symptoms in Japanese adults.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1857145","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:17:47Z","timestamp":1785219467000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reliability and convergent validity of the Japanese version of the Adult ADHD Investigator Symptom Rating Scale: a multicenter, longitudinal, non-interventional study"],"prefix":"10.3389","volume":"17","author":[{"given":"Akira","family":"Iwanami","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Showa Medical University","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Showa Medical University","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, New Drug Development Division, Otsuka Pharmaceutical Co., Ltd.","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Sakayoshi","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, New Drug Development Division, Otsuka Pharmaceutical Co., Ltd.","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamato","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Otsuka Pharmaceutical Co., Ltd.","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Otsuka Pharmaceutical Co., Ltd.","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Oberdhan","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development and Commercialization, Inc., Global Integrated Evidence & Innovation","place":["Rockville, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Machizawa","sequence":"additional","affiliation":[{"name":"Department of Digital Health and Science, Signant Health","place":["Blue Bell, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Busner","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Virginia Commonwealth School of Medicine","place":["Richmond, VA, United States"]},{"name":"Department of Science and Medicine, Signant Health","place":["Blue Bell, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenard A.","family":"Adler","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, NYU Grossman School of Medicine","place":["New York, NY, United States"]},{"name":"Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30167-0","article-title":"ADHD in children and young people: prevalence, care pathways, and service provision","volume":"5","author":"Sayal","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.1555","article-title":"The structure of adult ADHD","volume":"26","author":"Adler","year":"2017","journal-title":"Int J Methods Psychiatr Res"},{"key":"B3","unstructured":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)\n          \n          2022"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2021.05.019","article-title":"Review: Adult outcome as seen through controlled prospective follow-up studies of children with attention-deficit\/hyperactivity disorder followed into adulthood","volume":"61","author":"Cherkasova","year":"2022","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12402-016-0208-3","article-title":"The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization World Mental Health Surveys","volume":"9","author":"Fayyad","year":"2017","journal-title":"Atten Defic Hyperact Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1017\/S003329171100153X","article-title":"The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)","volume":"42","author":"Bernardi","year":"2012","journal-title":"Psychol Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.4.716","article-title":"The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication","volume":"163","author":"Kessler","year":"2006","journal-title":"Am J Psychiatry"},{"key":"B8","first-page":"4","article-title":"Epidemiological study of adult ADHD in Japan: Prevalence of adult ADHD","volume":"3","author":"Uchiyama","year":"2012","journal-title":"J Child Brain Dev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.chi.0000189134.97436.e2","article-title":"Young adult outcome of hyperactive children: adaptive functioning in major life activities","volume":"45","author":"Barkley","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hec.2907","article-title":"The effects of childhood ADHD on adult labor market outcomes","volume":"23","author":"Fletcher","year":"2014","journal-title":"Health Econ"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2012.271","article-title":"Clinical and functional outcome of childhood attention-deficit\/hyperactivity disorder 33 years later","volume":"69","author":"Klein","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v67n0403","article-title":"Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community","volume":"67","author":"Biederman","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083658","article-title":"ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials","volume":"390","author":"Zhang","year":"2025","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61684-6","article-title":"Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study","volume":"385","author":"Dalsgaard","year":"2015","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba1551","article-title":"ADHD, financial distress, and suicide in adulthood: A population study","volume":"6","author":"Beauchaine","year":"2020","journal-title":"Sci Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.4174","article-title":"Serious transport accidents in adults with attention-deficit\/hyperactivity disorder and the effect of medication: a population-based study","volume":"71","author":"Chang","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2019.128","article-title":"Suicidal behaviour among persons with attention-deficit hyperactivity disorder","volume":"215","author":"Fitzgerald","year":"2019","journal-title":"Br J Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/1087054713515748","article-title":"The relationships between ADHD and social functioning and participation in older adults in a population-based study","volume":"19","author":"Michielsen","year":"2015","journal-title":"J Atten Disord"},{"key":"B19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00019053-200523010-00008","article-title":"Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder","volume":"23","author":"Secnik","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.21290","article-title":"Economic burden of attention-deficit\/hyperactivity disorder among adults in the United States: a societal perspective","volume":"28","author":"Schein","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-10-99","article-title":"A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment","volume":"10","author":"Shaw","year":"2012","journal-title":"BMC Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/10870547231158572","article-title":"Functional impairments associated with ADHD in adulthood and the impact of pharmacological treatment","volume":"27","author":"Kosheleff","year":"2023","journal-title":"J Atten Disord"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m14934","article-title":"Solriamfetol for attention-deficit\/hyperactivity disorder in adults: A double-blind placebo-controlled pilot study","volume":"84","author":"Surman","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s40263-022-00938-w","article-title":"A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit\/hyperactivity disorder","volume":"36","author":"Nasser","year":"2022","journal-title":"CNS Drugs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001575","article-title":"Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit\/hyperactivity disorder: Results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials","volume":"42","author":"Adler","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40263-024-01120-0","article-title":"An open-label extension study assessing the long-term safety and efficacy of viloxazine extended-release capsules in adults with attention-deficit\/hyperactivity disorder","volume":"38","author":"Childress","year":"2024","journal-title":"CNS Drugs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/10870547231222260","article-title":"A single-blind, placebo controlled trial of triple beaded mixed amphetamine salts in DSM-5 adults with ADHD assessing effects throughout the day","volume":"28","author":"Adler","year":"2024","journal-title":"J Atten Disord"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/1087054715580393","article-title":"Pilot study of droxidopa with carbidopa in adults with ADHD","volume":"23","author":"Adler","year":"2019","journal-title":"J Atten Disord"},{"key":"B29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","article-title":"Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation","volume":"8","author":"Wild","year":"2005","journal-title":"Value Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1087054709347435","article-title":"Validation of the adult ADHD investigator symptom rating scale (AISRS)","volume":"14","author":"Spencer","year":"2010","journal-title":"J Atten Disord"},{"key":"B31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ridd.2017.02.011","article-title":"Psychometric properties of the Japanese version of the adult attention-deficit hyperactivity disorder (ADHD) self-report scale (ASRS-J) and its short scale in accordance with DSM-5 diagnostic criteria","volume":"63","author":"Takeda","year":"2017","journal-title":"Res Dev Disabil"},{"key":"B32","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"B33","unstructured":"COSMIN study design checklist for patient-reported outcome measurement instruments\n          \n          \n            \n              Mokkink\n              LB\n            \n            \n              Prinsen\n              CAC\n            \n            \n              Patrick\n              DL\n            \n            \n              Alonso\n              J\n            \n            \n              Bouter\n              LM\n            \n            \n              de Vet\n              HCW\n            \n          \n          \n          2019"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11165-016-9602-2","article-title":"The use of Cronbach\u2019s alpha when developing and reporting research instruments in science education","volume":"48","author":"Taber","year":"2018","journal-title":"Res Sci Educ"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J Chiropr Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-018-1798-3","article-title":"COSMIN guideline for systematic reviews of patient-reported outcome measures","volume":"27","author":"Prinsen","year":"2018","journal-title":"Qual Life Res"},{"key":"B37","article-title":"Measurement properties and clinically meaningful change of the adult ADHD investigator symptom rating scale (AISRS) [poster","volume-title":"Apsard 2022","author":"Meunier","year":"2022"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1857145\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:17:49Z","timestamp":1785219469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1857145\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":37,"alternative-id":["10.3389\/fpsyt.2026.1857145"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1857145","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1857145"}}